Peer Review History

Original SubmissionAugust 31, 2019
Decision Letter - Vincenzo Lionetti, Editor

PONE-D-19-23641

In vivo elongation of thin filaments results in heart failure

PLOS ONE

Dear Dr. Gregorio,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR: The authors should better highlight limitations of the study. Moreover, it is important to measure capillary density, cardiomyocyte size and collagen content.

==============================

We would appreciate receiving your revised manuscript by Nov 15 2019 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Vincenzo Lionetti, M.D., PhD

Academic Editor

PLOS ONE

Journal Requirements:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The Authors have developed a novel transgenic mouse model stably overexpressing Lmod2 in cardiac tissues in a reversible manner, in order to study the consequences of longer thin filaments. This sudy confirms that the maintenance of thin filament lengths is critical for heart muscle function and shows that mammalian intact hearts with longer thin filaments in vivo result in a complex cardiomyopathy. The paper is well written, the methods appear appropriate and the results are clearly stated and quite interesting.

Reviewer #2: Review of PONE-D-19-23641 submitted by Mi-Mi et al.

Title of MS: In vivo elongation o thin filaments results in heart failure.

This is a beautifully written, well documented and carefully deduced conclusions on the effects of increasing the amount of a thin filament pointed end associated protein leiomodin-2 in mouse models. Increasing the level of this protein resulted in a 10 to sometimes 26% longer thin filaments. Examination of the effects of raising the intracellular levels of lmod2 also lead to effects on the Z-Bands and intercalated discs in the mouse hearts.. The sarcomeres from muscle expressing this higher level of Lmod2 resulted in a loss of upto 50% loss of contractile forces resulting in cardiac failure. It is very impressive that their experiments in which they lower the high levels on Lmod2 lead to a reversal of the effects of the high levels of Lmod2. The authors have previously demonstrated that lowering the amount of Lmod in the cardiomyocytes lead to shorter filaments, and also cardiac defects. The combination of these two reports demonstrates the importance of Lmod in the health of the heart. This manuscript is a first-rate contribution to our understanding of the role of Lmod2 in myofibril assembly, and how changing the normal levels of Lmod2 can lead to cardiac failure. This manuscript should be published without changes.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachments
Attachment
Submitted filename: PONE-D-19-23641 Mi-Mi et al.docx
Revision 1

From Academic Editor (1 of 2): “The authors should better highlight limitations of the study.”

The only limitation of this study that we are aware of is that we are not able to study the mice homozygous for the Lmod2 transgene. This is addressed as follows:

Heterozygous Lmod2 transgene-positive (Lmod2-TG) mice do not die prematurely and are able to breed when Lmod2-TG males are crossed with Lmod2 transgene-null (NTG) females. However, the majority of Lmod2-TG females do not survive through pregnancy, potentially due to volume-induced cardiac stress (n = 10; percent fatality = 60%), and homozygous Lmod2 transgenic pups do not survive past post-natal day 7 (n = 3 litters; percent fatality = 100%).

Thus, analysis of homozygous Lmod2 transgenic mice could not be included in this study. See page16, lines 313-318.

From Academic Editor (1 of 2): “Moreover, it is important to measure capillary density, cardiomyocyte size and collagen content.”

We are a bit confused about the question the Editor would like us to address with this request but, hopefully, we sufficiently addressed the request below. In short, we do not have any data that demonstrates statistically significant differences between Lmod2-TG and NTG mice, in terms of capillary density, cardiomyocyte size or collagen content before Lmod2-TG hearts display cardiac disease remodeling (P30; Fig. 2). In comparison, cardiac thin filament lengths are already 3% longer at P1, and contractile force reduced by 47% at P15.

- RE: Capillary density

We deduce that this query arose from two possible scenarios: (1) increases in capillary density accompany hypertrophied hearts; or (2) decreases in capillary density give way to tissue hypoxia, cell death and interstitial fibrosis. Both scenarios could lead to contractile dysfunction and heart failure.

Note, #1 is unlikely a primary factor contributing to heart failure because we only observe cardiac hypertrophy (i.e., increased heart mass) in Lmod2-TG mice at P60 (Supporting Table S3), when disease remodeling has already taken place.

As for #2, we found that: (i) levels of interstitial fibrosis in Lmod2-TG are only significantly elevated after P30 (Fig. 2C), and not at P1 and P7 as indicated by Picrosirius Red-staining and quantification (%PSR) (which is now added as a Supporting Figure S5A; n = 4-10; error bars = SEM); and (ii) passive tension average (a criterion linked to fibrosis levels) between NTG and Lmod2-TG is not statistically significant at P15 (Fig. 5C).

It is also important to note that we do not detect changes in the levels of Lmod1, the leiomodin isoform predominantly expressed in smooth muscles, as well as other markers of pathological capillary densities, in our Lmod2-TG model (Supporting Table S1). Together, these data suggest that changes in capillary density are unlikely a primary contributing factor to heart failure in the Lmod2-TG mice.

Added: Supporting Figure S5A

Updated: Supporting Table S1

- RE: Cardiomyocyte size

Surface areas of neonatal cardiomyocytes extracted from P2 Lmod2-TG and NTG littermates at day 1 (D1), day 3 (D3) and day 5 (D5) post-plating were measured using ImageJ. No statistically significant difference was detected at all time points examined. These data are now added as a Supporting Figure S5B (n = 30 each; error bars = SEM).

Added: Supporting Figure S5B

- RE: Collagen content

We used Picrosirius-Red staining to detect collagenous deposits (see above). No significant difference between NTG and Lmod2-TG in the percent Picrosirius Red-stained (%PSR) P1 and P7 LV sections was detected (n = 4-10). In addition, we detected no significant difference in collagen gene expressions in our RNA-Seq between P7 NTG and Lmod2-TG. These data have been added to Supporting Table S1 (P < 0.05; n = 3 per genotype).

Updated: Supporting Table S1

Attachments
Attachment
Submitted filename: PONE-D-19-23641_Response to Reviewers.docx
Decision Letter - Vincenzo Lionetti, Editor

In vivo elongation of thin filaments results in heart failure

PONE-D-19-23641R1

Dear Dr. Gregorio,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

With kind regards,

Vincenzo Lionetti, M.D., PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This paper is well written and the study has been properly conducted. The data as to the role of Lmod2 in cardiac failure are novel and of interest.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Formally Accepted
Acceptance Letter - Vincenzo Lionetti, Editor

PONE-D-19-23641R1

In vivo elongation of thin filaments results in heart failure

Dear Dr. Gregorio:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

For any other questions or concerns, please email plosone@plos.org.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Vincenzo Lionetti

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .